A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer - NCT00663832-48201(Clinical Trial 216763)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Detroit |
|
State:
|
|
MI |
| Zip Code: |
|
48201 |
| Conditions: |
|
Prostate Cancer |
| Purpose: |
|
This Phase Ib dose escalation study is designed to characterize the safety, tolerability and
preliminary efficacy of i.v. panobinostat (LBH589) in combination with docetaxel and
prednisone in the 1st line treatment of patients with hormone refractory prostate cancer.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion criteria:
- HRPC patients
- Evidence of disease progression
- Self care, able to perform light work activities
- Willing to use contraception throughout the study and for 12 weeks after study
completion
Exclusion criteria:
- History of other cancers not curatively treated with no evidence of disease for more
than 5 years.
- Prior radiotherapy within 3 weeks of starting study treatment
- Prior radiopharmaceuticals (strontium, samarium).
- Impaired cardiac function
- Heart disease
- Liver or renal disease with impaired functions.
Other protocol-defined inclusion/exclusion criteria may apply |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
October 7, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|